Cue Biopharma

CUE Lead: Phase 2 7 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-16

Catalyst timeline

CUE-401 readout2H 2026CUE-401 readout, 2H 2026, material
CUE-221 Ph2 toplinelate 3Q 2026CUE-221 Ph2 topline, late 3Q 2026, thesis-defining
CUE-221 IND filinglate 3Q 2026CUE-221 IND filing, late 3Q 2026, material
CUE-401 Ph1 startEnd of 2026CUE-401 Ph1 start, End of 2026, notable
CUE-221 Ph2b start4Q 2026CUE-221 Ph2b start, 4Q 2026, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (6 active programs)

CUE-401

Protein Target: TGF-β, IL-2

Undisclosed indication Preclinical

CUE-501

Protein Target: B cells

Undisclosed indication Preclinical Boehringer Ingelheim International

CUE-101

Protein Target: HPV

Head and Neck Cancer Phase 1 ImmunoScape NCT03978689

CUE-102

Protein Target: WT1

Undisclosed indication Phase 1 ImmunoScape NCT05360680

CUE-221

Protein Target: IgE

Food Allergy Preclinical
Allergic Diseases Phase 2 Ascendant Health Sciences

Technology platforms

Immuno-STAT

Modular biologics platform designed to selectively engage and modulate disease-specific T cells for autoimmune, inflammatory, and oncology indications. Enables selective Treg induction/expansion, targeted cell depletion via anti-viral T cell redirection, and tumor-specific T cell activation.

Targets: TGF-β, IL-2, T cells, Tregs

Biotech Distilled coverage (7)

2026-08-22 UPDATE: Cue Biopharma (CUE) - The CEO’s 13D and the 30% Air Pocket 🔒 Paid
2026-08-15 UPDATE: Cue Biopharma (CUE) - A $153 Million Loss That Isn’t a Loss 🔒 Paid
2026-08-04 UPDATE: Cue Biopharma (CUE) - The IND Nobody Noticed 🔒 Paid
2026-07-13 UPDATE: Cue Biopharma (CUE) - The CMO Chair Gets Filled, the PIPE Overhang Bites 🔒 Paid
2026-07-10 UPDATE: Cue Biopharma (CUE) - The $50M Vote of Confidence and the CSU Clock 🔒 Paid
2026-06-02 UPDATE: Cue Biopharma (CUE) - The Horizon Crew Takes the Board
2026-05-20 Cue Biopharma, Inc. (CUE) — Scientific Deep Dive for CUE-221 and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.